Sarissa Capital Management LP
CIK 1577524 · View on SEC EDGAR ↗
- Portfolio value
- $177.9M
- Positions
- 10
- As of
- June 30, 2026
Portfolio value QoQ: +12.8% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 8
- Effective number of positions
- 6.0
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 0.29% Est. buys $489,882 · sells $5,458,258
Median holding: 4.0 quarters Tracked Q4 2024–Q2 2026 · 76.9% still held
- New positions
- 1
- Increased
- 1
- Decreased
- 1
- Closed
- 1
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Annualized: +21.3% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 97.9% · Options excluded: 0.0%
Sector breakdown
Full portfolio 10 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| INVA Innoviva, Inc. - Common Stock | $42,935,617 | 24.14% | 1,890,604 | $-6,715,518 | Down ×2 | ||
| IRWD Ironwood Pharmaceuticals, Inc. - Class A Common Stock | $38,684,153 | 21.75% | 9,188,635 | $6,432,044 | |||
| AMRN Amarin Corporation plc - American Depositary Shares | $26,673,916 | 15.00% | 1,673,395 | $2,476,624 | |||
| NBIX Neurocrine Biosciences, Inc. - Common Stock | $19,639,889 | 11.04% | 116,533 | $4,287,832 | |||
| CYTK Cytokinetics, Incorporated - Common Stock | $19,476,393 | 10.95% | 228,623 | $4,407,851 | |||
| LNTH Lantheus Holdings, Inc. - Common Stock | $18,517,994 | 10.41% | 166,919 | $5,857,188 | |||
| BHVN Biohaven Ltd. Common Shares | $8,664,803 | 4.87% | 582,312 | $3,900,266 | Up ×2 | ||
| REGN Regeneron Pharmaceuticals, Inc. - Common Stock | $2,612,633 | 1.47% | 4,190 | $-624,729 | |||
| VOR Vor Biopharma Inc. - Common Stock | $467,596 | 0.26% | 25,399 | $14,478 | |||
| BIIB Biogen Inc. - Common Stock | $205,257 | 0.12% | 950 | Up ×1 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| BIIB | $205,257 | 950 | 0.12% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| INVA | Trimmed | -240K | -$6.7M |
| IRWD | Price move only | +0 | +$6.4M |
| LNTH | Price move only | +0 | +$5.9M |
| CYTK | Price move only | +0 | +$4.4M |
| NBIX | Price move only | +0 | +$4.3M |
| BHVN | Bought more | +19K | +$3.9M |
| AMRN | Price move only | +0 | +$2.5M |
| REGN | Price move only | +0 | -$625K |
| VOR | Price move only | +0 | +$14K |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| GILD | March 31, 2025 | 262,080 | $24,208,330 | 29.3% |
| AMRNXXXX | June 30, 2025 | 24,850,623 | $11,135,564 | No longer tracked |
| VORXXXX | Sept. 30, 2025 | 508,016 | $822,986 | No longer tracked |